Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | EYA2 | O00167 | 1/20 | 0.78 |
| ▸ | APP | P05067 | 1/20 | 0.78 |
| ▸ | ACE | P12821 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 2/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | DRD3 | P35462 | 1/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL6418284 | 1.00 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10937476 | 1.00 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10906870 | 1.00 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL2471967 | 1.00 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL247531 | 0.97 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL30569658 | 0.97 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1363382 | 0.97 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL224117 | 0.97 | TDP1 (0.82) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL9295873 | 0.95 | TDP1 (0.70) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10639065 | 0.95 | TDP1 (0.70) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1743034-B1 | PEPTIDE SUBSTRATES RECOGNISABLE BY A BOTULINUM TOXIN A, BONT/A AND THE USE THEREOF | PHARMALEADS (FR) | 2007-12-12 | — | — | EP | claimed |
| EP-1743034-A2 | PEPTIDE SUBSTRATES RECOGNISABLE BY A BOTULINUM TOXIN A, BONT/A AND THE USE THEREOF | Pharmaleads (FR) | 2007-01-17 | — | — | EP | claimed |
| WO-2005121354-A2 | PEPTIDE SUBSTRATES RECOGNISABLE BY A BOTULINUM TOXIN A, BONT/A AND THE USE THEREOF | PHARMALEADS (FR) | 2005-12-22 | — | — | WO | claimed |
| US-20120045533-A1 | THIN FILM BUFFER LAYER SOLUTION DEPOSITION ASSEMBLY | AERIS CAPITAL SUSTAINABLE IP LTD. (KY) | 2012-02-23 | — | — | US | disclosed |
| WO-2011143275-A2 | THIN FILM BUFFER LAYER SOLUTION DEPOSITION ASSEMBLY | NANOSOLAR, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110257092-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. | 2011-10-20 | — | — | US | disclosed |
| US-20110160126-A1 | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders | OSPREY PHARMACEUTICALS LIMITED (CA) | 2011-06-30 | — | — | US | disclosed |
| US-7913453-B2 | Potato quality | SYNGENTA CROP PROTECTION, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2290454-A1 | Toner having titania and processes thereof | Xerox Corporation (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-1743034-B1 | PEPTIDE SUBSTRATES RECOGNISABLE BY A BOTULINUM TOXIN A, BONT/A AND THE USE THEREOF | PHARMALEADS (FR) | 2007-12-12 | — | — | EP | disclosed |
| EP-1743034-A2 | PEPTIDE SUBSTRATES RECOGNISABLE BY A BOTULINUM TOXIN A, BONT/A AND THE USE THEREOF | Pharmaleads (FR) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005121354-A2 | PEPTIDE SUBSTRATES RECOGNISABLE BY A BOTULINUM TOXIN A, BONT/A AND THE USE THEREOF | PHARMALEADS (FR) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257092-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | GLP1R, GCGR, GCG | ADRA2A 864/4885TDP1 4652/4885EYA2 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.